Broadly Neutralizing Antibody (bNAb) Combinations

As with antiretroviral combinations used in treatment, a strategy to protect against HIV will likely require two or more bNAbs that target different parts of the virus. There are many factors to consider when selecting bNab combinations, including how many bNabs and which ones work best together. Here we outline the bNAb combinations being explored in early clinical studies.

Regimen	Phase	Status	Route	Research Institute	Trial Name
	I	Completed	IV	VRC	VRC 611
	I	Completed	IV	CAPRISA	CAPRISA 012A
	I	Completed	IV, SC	CAPRISA	CAPRISA 012B SAMBA trial II
	I	Ongoing	IV, SQ	VRC	VRC 617
	I	Planned	IV	HVTN, HPTN	HVTN 141/ HPTN 105
	II	Ongoing	SQ	CAPRISA	CAPRISA 012C/ SAMBA trial III
	II	Ongoing	IV	HVTN, HPTN	HVTN 206/ HPTN 114

CASPRISA: Centre for the AIDS Programme of Research in South Africa; **HPTN**: HIV Prevention Trials Network; **HVTN**: HIV Vaccine Trials Network; **IV**: intravenous; **SC**: subcutaneous; **VRC**: Vaccine Research Center

bNAb Key								
V1/V2-glycan				V3-glycan			CD4 binding site	
								
CAP256V2LS	CAP256J3LS	ePGDM1400v9-LS	PGDM1400LS	PGT121	PGT121.414.LS	ePGT121v1-LS	VRC07-523LS	VRC01-23LS

AVAC
Advocacy. Access. Equity.
December 2025